Sarah Meeks - MaxCyte Senior Development

MaxCyte Management Efficiency

The company has return on total asset (ROA) of (0.1125) % which means that it has lost $0.1125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.16) %, meaning that it created substantial loss on money invested by shareholders. MaxCyte's management efficiency ratios could be used to measure how well MaxCyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2024. Return On Capital Employed is likely to gain to -0.18 in 2024. At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 19.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 9.7 M in 2024.

Similar Executives

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. Maxcyte operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 84 people. MaxCyte (MXCT) is traded on NASDAQ Exchange in USA. It is located in 9713 Key West Avenue, Rockville, MD, United States, 20850 and employs 143 people. MaxCyte is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

MaxCyte Leadership Team

MaxCyte Stock Performance Indicators

Additional Tools for MaxCyte Stock Analysis